I want to delve into and highlight high-impact research coming out of Arab and North African countries.

As the Inflation Reduction Act empowers Medicare to negotiate drug prices based in part on clinical benefit, and as the FDA more closely scrutinizes accelerated approvals, a fundamental question has b...

Improving how the FDA disseminates already-public information about approved drugs may be unsexy, but it would be a big step toward the era of “radical transparency.”

A lot of students and young professionals ask me how to get into biotech strategy, consulting, or investing (esp. venture capital).

This list consists of writing that ticked two boxes: 1) did I think about the article again more than a week after reading it?, and 2) was it written for a popular audience? So, academic papers, inclu...

This week featured a rare crossing of the streams, as the buttoned-down world of cancer research met the buzzy world of exercise and wellness.  One result: a randomized controlled study of exercise in...

The CHALLENGE trial ignited social media with its great story of exercise as a cancer therapeutic. But liking a conclusion is not a reason to stop thinking.

Part 1: What people say

Anti-obesity drugs are showing promise for an ever-expanding list of diseases

Let us celebrate one of the great social and technical breakthroughs of the 2010s: the invention of the “Bic for Her,” a biro so ergonomic even the wife could use it—and so pretty she would want to.

Pociredir works, Mitapivat may work

One startup has said genetically modified microbe could prevent cavities. Experts, though, have safety concerns.

One regulatory stroke could save more American lives than a decade of health campaigns. You have the pen.

President Trump could have walked softly and carried a big stick. As pharmaceutical investors see it, he instead stomped loudly and wielded a wet noodle.

Challenges may arise as there could be unintended consequences on oncologic drug development, access, and innovation.